As of 2026, across the five key markets, the United States, the European Union, China, South Korea, and Brazil, injectable dermal fillers are generally regulated as high-risk medical devices.
Significant differences exist in the applicable legal provisions, risk-classification approaches, registration pathways, and practitioner qualification requirements. These differences directly affect market entry thresholds, clinical evidence expectations, and distribution and promotional strategies.
This article provides a concise overview of the key regulatory requirements for dermal fillers or dermal filler injections in these five major markets.
Key Findings:
1. European Union:Hyaluronic acid and other dermal fillers, even when marketed solely for aesthetic purposes, are regulated as Annex XVI, Group 3 products under EU MDR 2017/745, subject to Common Specifications (EU) 2022/2346. Dual‑purpose fillers must satisfy both MDR medical device requirements and Annex XVI requirements, and all products must obtain CE marking, demonstrate clinical evidence, comply with post‑market surveillance, register in the European Database on Medical Devices (EUDAMED), and carry a Unique Device Identifier (UDI).
2. United States:Most dermal fillers are classified by the FDA as Class III medical devices, requiring PMA (Pre-market Approval) review. They are prescription-only products administered exclusively by licensed healthcare professionals, accompanied by specific safety warnings.
3. China:The NMPA categorizes injectable sodium hyaluronate based on intended use and mechanism of action. Most dermal filler injectables are explicitly designated as Class III medical devices, requiring registration under the Measures for the Administration of Registration and Recordation of Medical Devices and subject to UDI management requirements.
4. South Korea:The Ministry of Food and Drug Safety (MFDS) implements risk-based classification through the Medical Device Act. Dermal fillers are placed in high-risk categories, typically Class III or Class IV soft-tissue injection devices. Products require product approval from MFDS, KGMP certification, and a designated Korea License Holder (KLH); clinical data is required where no predicate device exists, while substantial equivalence to a predicate device may be demonstrated in lieu of clinical data. There is separate oversight of medical facilities and practitioner qualifications under the Medical Service Act.
5. Brazil:Agência Nacional de Vigilância Sanitária (ANVISA) implements risk-based classification through its medical device framework (RDC No. 751/2022 and GMP rules). Injectable dermal fillers, including medical cross-linked sodium hyaluronate gels, are placed in the highest-risk category (Class IV medical devices). Products require pre-market registration (Registro) with ANVISA, a valid B-GMP certificate, and a designated Brazil Registration Holder (BRH); clinical data is required where applicable. Medical facilities and practitioner qualifications are subject to separate oversight.
Past Review: Top 9 Countries for Dermal Filler Wholesale & Treatments: 2025 Key Trends
Dermal Filler Regulations Overview (2026 Updated)
Market | Core Framework | Regulatory Status of Dermal Fillers | Typical Pre-market Route | Who can Inject (high-level) | Key 2026 Trend |
EU | Regulation (EU) 2017/745 (MDR) Implementing Regulation (EU) 2022/2346 (Common Specifications for Annex XVI) | Aesthetic dermal fillers without medical purpose are Annex XVI, Group 3 products; most are classified as class III. | MDR-level CE marking with notified-body review and mandatory Common Specifications (CS) for Annex XVI fillers. | Only “appropriately trained healthcare professionals who are qualified or accredited in accordance with national law”, typically physicians; some Member States allow dentists / trained nurses under conditions. | MDR Annex XVI regime and CS fully in force; transitional deadlines for legacy fillers run to 2027, depending on conditions. |
US | Federal Food, Drug, and Cosmetic Act (FD&C Act) FDA Center for Devices and Radiological Health (CDRH) | Dermal fillers (soft tissue fillers) are prescription-use implantable medical devices; FDA-approved products are treated as high-risk devices with PMA-type review. | Pre-market approval (PMA) with clinical trials and Summary of Safety and Effectiveness Data (SSED) for each new filler or major new indication. | FDA: only licensed, appropriately trained healthcare professionals; details (NP, PA, RN, etc.) set by each state’s scope-of-practice laws. | FDA updated online recommendations to emphasize delayed-onset inflammation, bans on needle-free injection and unapproved body-site uses. |
China | Good Manufacturing Practice for Medical Devices Medical Device Classification Catalogue (NMPA Order No. 143, 2017) | Sodium hyaluronate injectable fillers for augmenting tissue volume or improving skin condition are class III medical devices. | Class III NMPA registration with type testing in China, clinical evaluation, and full QMS documentation. | Aesthetic injections are medical acts in licensed medical institutions; performed by licensed physicians, with nurses assisting under medical direction. | NMPA has clarified sodium hyaluronate classifications, confirming filler and skin-improvement injections as class III devices and tightening lifecycle supervision. |
South Korea | Dermal fillers are classified by MFDS as high-risk (Class III or Class IV soft-tissue injection devices). | Highest-risk devices require a full MFDS technical review (STED format dossier), clinical data where needed, and KGMP compliance. | Only licensed physicians and dentists (within their professional scope) may inject under the Medical Service Act; nurses assist under physician supervision. | Korea remains a major manufacturing and export hub for hyaluronic acid fillers; fillers remain strictly regulated under the Medical Device Act. | |
Brazil | Brazilian medical device framework (RDC No. 751/2022, ANVISA GMP rules) | Injectable dermal fillers (including medical cross-linked sodium hyaluronate gels) are classified as Class IV / Grade 4 medical devices (highest risk). | Pre-market “Registro” with full technical dossier, clinical data (where applicable), ANVISA review; B-GMP and Brazil Registration Holder (BRH) required. | Only by licensed physicians and dentists (within their professional scope), and by nurses working under physician supervision; biomedical scientists and pharmacists may also perform injections within the scope authorized by their respective Federal Councils; non-medically licensed injectors are not legally permitted. | ANVISA is tightening registration conditions and post-market vigilance for high-risk fillers; parallel cosmetics/“beauty-injection” abuses remain a public health issue. |
Latest Regulatory (2026) for Dermal Filler Injections Across Regions
European Union (EU)
● Legal basis: Regulation (EU) 2017/745 (MDR); Annex XVI, Group 3explicitly lists dermal fillers (“Substances, combinations of substances, or items intended to be used for facial or other dermal or mucous membrane filling by subcutaneous, submucous or intradermal injection or other introduction, excluding those for tattooing.”).
● Implementing Regulation (EU) 2022/2346 sets Common Specifications (CS) for Annex XVI devices; Annex IV covers dermal fillers, including strict risk‑management and labelling such as: “Only to be administered by appropriately trained healthcare professionals…” and “Not for persons under 18 years”.
Compliance focus for manufacturers/distributors: correct Annex XVI classification and risk class; CE certificate referencing MDR + 2022/2346 CS; labelling and promotion fully aligned with CS and national advertising rules.
United States
● FDA defines dermal fillers as medical device implants for specific anatomical indications;only FDA‑approved fillers (listed on “FDA‑Approved Dermal Fillers”) should be used.
● The “Dermal Fillers (Soft Tissue Fillers)” page summarises approved uses, major risks (vascular occlusion, blindness, delayed inflammation, infection),and explicitly warns against: needle‑free injection devices, over‑the‑counter fillers, and unapproved large‑volume body uses.
Compliance focus: ensure every product is an FDA‑approved filler for the promoted indication; use official SSED and labelling from the FDA device database as the master reference; distributors must avoid suggesting off‑label areas or non‑needle delivery.
China (Mainland)
● Medical devices are regulated under a risk-based classification system established by the Medical Device Classification Catalogue (NMPA Order No. 143, 2017). Notice of NMPA on the Management Category of Sodium Hyaluronate Products for Medical Purposes (2022 No. 103)further specifies that: “Sodium hyaluronate used as injectable fillers to augment tissue volume or injected into dermis to improve skin condition are class III medical devices.”
● ForMedical Device Distribution: Provisions for Supervision and Administration of Medical Device Distribution
Compliance focus: treat HA fillers as class III devices, plan for local type testing and clinical studies, and ensure Chinese labelling/IFU strictly match NMPA‑approved indications; only supply licensed medical institutions.
South Korea
● MFDS manages a four‑class risk-based classification system under the Medical Device Act. Dermal fillers are classified as Class III or Class IV medical devices (soft‑tissue injection devices), both requiring full pre‑market review by MFDS and KGMP
Compliance focus: prepare STED‑format technical dossiers for MFDS review; complete KGMP certification; designate a licensed Korea License Holder (KLH) as the mandatory local registration holder. Distributors must verify MFDS product approvals and ensure fillers are positioned strictly as medical‑procedure products, not simple cosmetics.
Brazil
● ANVISA classifies injectable dermal fillers (including medical cross‑linked sodium hyaluronate gels) as Class IV medical devices, i.e., the highest‑risk category under Brazil’s medical device framework (RDC No. 751/2022).
● Class IV devices are subject to mandatory pre‑market Registro (registration) with ANVISA prior to commercialization. GMP technical requirements are governed by RDC 665/2022; the administrative procedures for B‑GMP certification review and inspection are governed by RDC 687/2022; and the administrative procedures for obtaining B‑GMP certification (including petition, audit plan submission, and certificate issuance) are governed by RDC 497/2021.
● ANVISA also enforces strict requirements on labeling and approved indications: packaging and Instructions for Use (IFU) must be in Portuguese, clearly indicating the risk class (Class IV), intended use, and Brazil Registration Holder (BRH) information, in accordance with RDC 751/2022 labeling requirements. All promotional and marketing materials must remain strictly within ANVISA‑registered indications; positioning Class IV injectable devices as a “non‑medical beauty service” is not permissible.
Compliance focus: MDSAP participation is strongly recommended to accelerate certification and extend the validity of the B‑GMP certificate; prepare a complete Registro‑level dossier aligned with ANVISA’s IMDRF‑ToC and including ANVISA‑aligned clinical evidence; designate a reliable Brazil Registration Holder (BRH) as the local registration holder. Ensure all labeling and marketing materials comply strictly with ANVISA‑approved indications and Brazilian medical‑practice rules.
‣ Note: MDSAP (Medical Device Single Audit Program) is a global quality system audit program coordinated by regulatory authorities in the United States, Canada, Brazil, Australia, and Japan, allowing a single audit to satisfy the GMP requirements of multiple regulators, including Brazil’s B–GMP requirements. For Brazil specifically, manufacturers holding a valid MDSAP certificate with Brazil (ANVISA) in scope are eligible for an extended B‑GMP certificate validity of four years, compared to the standard two‑year validity applicable to non‑MDSAP manufacturers.
Jingjia Medical: Hyaluronic Acid Fillers and OEM Collaboration
Jingjia Medical specializes in medical-grade sodium hyaluronate gels for applications including surgical anti-adhesion, ophthalmic viscoelastic devices, joint lubrication, and minimally invasive aesthetic fillers. Our brand HAFILLER is renowned for quality and performance across medical and aesthetic applications.
• 2008: HAFILLIER medical-grade sodium hyaluronate gel received CE certification
• June 2016: Recognized in Hangzhou for excellence in R&D
• 2018: Successfully passed the MDSAP, meeting regulatory requirements across multiple international markets.
• November 2018: Designated a High-Tech Enterprise R&D Center in Zhejiang Province
If you’re seeking a reliable dermal filler supplier for your dermal beauty business or looking to launch your own private-label line, Jingjia Medical specializes in sodium hyaluronate injection manufacturing with competitive dermal filler cost.
We offer hyaluronic acid in bulk for global distributors, plus full OEM customization for hyaluronic acid injections—from formulation to packaging.
With 30+ years of expertise and CE-certified production, visit Jingjia Medical to streamline your supply chain and elevate your brand today.
FAQs on the Global Dermal Filler Market
1. Which country currently has the hottest and most promising dermal filler market?
Global reports still show North America (especially the US) as the largest dermal filler market by revenue and procedure volume. Meanwhile, the Asia-Pacific region, led by China and South Korea, along with Latin America’s emerging market represented by Brazil, is the fastest-growing area, driven by rising demand and medical tourism.
2. What qualifications are required for non-physician injectors (e.g., nurses, beauticians)?
• US: FDA says dermal fillers should only be injected by licensed, appropriately trained healthcare professionals. In practice, state law decides whether nurse practitioners, physician assistants,and registered nurses may inject (often yes, under specific protocols), while non‑medical aestheticians generally cannot inject legally.
• EU: Common Specifications require administration only by “appropriately trained healthcare professionals… in accordance with national law”, so most Member States restrict independent injection to doctors/dentists and allow nurses only with defined training and supervision.
• China, South Korea, Brazil: Filler injections are medical procedures in licensed medical institutions; they are normally performed by physicians, with nurses assisting under doctor supervision.
3. How often do medical aesthetic clinics need to renew their operating licenses or relevant certifications?
Renewal frequency is governed by health‑facility law, not device law, and varies:
• In China, medical institution licences are issued for multi‑year periods and renewed under national and provincial health‑administration rules.
• In the US and EU, clinics/med‑spas are licensed at the state or national level with 1–3‑year renewal cycles in many jurisdictions.
• South Koreaand Brazil use their own medical‑facility licensing systems.
4. What are the most promising dermal filler material segments at present?
Hyaluronic acid (HA) fillers remain the largest segment globally thanks to their safety, reversibility, and broad indications.
Biostimulatory and hybrid fillers, including calcium hydroxylapatite (CaHA), poly‑L‑lactic acid (PLLA), polycaprolactone (PCL), and HA‑hybrid products, are the fastest‑growing segments, offering longer duration and collagen‑stimulation benefits.
5. What is medical aesthetic tourism, and what is the situation in different countries?
• Medical tourism means travelling abroad for medical or aesthetic procedures, combining treatment with cost savings or access to specialist expertise.
For injectables, South Korea and Turkey stand out as 2025–2026 hubs for facial fillers and Botox, thanks to high‑volume specialist clinics and competitive pricing.
Countries such as Thailand and Mexico combine filler procedures with broader cosmetic and wellness tourism offerings.
Brazil is globally renowned for its plastic surgery and minimally invasive aesthetics, making it one of Latin America’s most important medical beauty destinations.
Disclaimer:
This guide provides general regulatory information on injectable dermal fillers as of March 2026 for reference only and does not constitute legal or regulatory advice. Requirements may vary by market and product; please consult the latest official guidance from the relevant authorities and seek advice from qualified professionals before making any decisions.
